Coegin Pharma AB

Equities

COEGIN

SE0020357754

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
3.01 ^SEK	+3.79%		-0.33%	-44.10%

2023	Coegin Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Coegin Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

BioStock: Coegin Pharma aims high in 2022

January 18, 2022 at 03:08 am EST

In 2021, Coegin Pharma reached a key milestone by launching a combined phase I/II clinical trial with AVX001 in actinic keratosis patients. Moreover, the company expanded its pipeline in order to pursue cancer indications and chronic kidney disease. BioStock reached out to Coegin's CEO Tore Duvold to hear what he had to say about the company's achievements during 2021 and his goals for 2022.

Read the interview with Tore Duvold at biostock.se:

https://www.biostock.se/en/2022/01/coegin-pharma-aims-high-in-2022/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/coegin-pharma-ab/r/biostock--coegin-pharma-aims-high-in-2022,c3487809

Latest news about Coegin Pharma AB

Coegin Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 19	CI
Coegin Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 19	CI
Coegin Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Coegin Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Coegin Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Coegin Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-27	CI
Coegin Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-26	CI
Coegin Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-23	CI
Coegin Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-24	CI
Coegin Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-18	CI
Coegin Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-23	CI
Coegin Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-23	CI
Coegin Pharma AS completed the acquisition of Follicum AB.	22-02-06	CI
Coegin Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-24	CI
Coegin Pharma Receives Final Approval for COAK Study	21-10-26	CI
Coegin Pharma AS agreed to acquire Follicum AB for SEK 35.4 million.	21-09-22	CI
Coegin Pharma : Shares Surge 12% On Regulatory Nod For Lead Drug Candidate	21-09-15	MT
Coegin Pharma Receives Approval from Ethics Committee for Clinical Trial	21-09-15	CI
Coegin Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-19	CI
Coegin Pharma AS completed the acquisition of Coegin Pharma AB in a reverse merger transaction	21-05-05	CI
Coegin Pharma Applies for Clinical Study Application	21-03-12	CI
Coegin Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-25	CI
Coegin Pharma AS agreed to acquire GoldBlue AB in a reverse merger transaction for SEK 53.9 million.	20-07-29	CI
GoldBlue AB Reports Unaudited Group Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-23	CI
GoldBlue AB has completed an IPO in the amount of SEK 23.985 million.	18-02-21	CI

Chart Coegin Pharma AB

Duration

Period

More charts

Company Profile

Coegin Pharma AB, formerly GoldBlue AB (publ) is a Sweden-based biotechnology company. The Company focuses on the development of small molecule therapies aimed at the key enzyme, which is known for its involvement in a variety of inflammatory diseases as well as in cancer. Coegin Pharma AB provides consulting and management services in drug development as well.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COEGIN PHARMA AB	-44.10%	4.45M
MODERNA, INC.	+25.69%	47.9B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research